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The effects of cyclophosphamide (CY) treatment on acute murine cytomegalo-
virus (MCMV) infection were studied to explore the potential usefulness of
MCMV as a means of detecting immune dysfunction and to identify host defense
mechanisms important for protection against MCMV. Conditions found optimal
for enhancing MCMV infection with CY included infecting adult mice with 2 x 105
PFU or more of virus and administering 80 mg or more of CY per kg 1 to 3 days
later. In addition to enhanced mortality, virus titers in lung, liver, and spleen were
elevated in CY-treated mice, and wet weights of liver, spleen, and thymus were
depressed when compared with those of infected but untreated mice. Treatment
with CY before MCMV challenge was not as efficient a means of enhancing
mortality as treatment after virus challenge. The effect that the time of CY
administration relative to infection had on mortality correlated with the effect of
such timing on natural killer cell activity. Animals treated before infection
exhibited depressed natural killer cell activity initially. However, they rapidly
recovered this response, and by 5 days postinfection they had the same level of
virus-augmented activity seen in untreated mice. In contrast, animals treated after
infection did not recover natural killer cell activity and were more likely to die. A
similar correlation was not obtained when the effects of CY on lymphocyte
responses to B and T cell mitogens were examined, nor were there striking
differences in pathology between the treatment groups. The data suggest an
important role for natural killer cells in host defense against MCMV. Also,
increased susceptibility to MCMV may provide a useful indicator of deficits in the
natural killer cell response.
Although murine and human cytomegalovi-
ruses usually produce benign infections in ma-
ture hosts, both are exacerbated by immunosup-
pressive treatment (5, 7, 9, 13, 14, 18, 20).
Recent studies on the effects of immunosuppres-
sion on murine cytomegalovirus (MCMV) have
focused on chronic or latent infections (7, 13, 14,
18, 19). However, several investigators have
considered the effects of immunosuppressive
treatment on the acute stage of infection (1, 10,
24), and the work presented here was undertak-
en to augment these studies. Our objectives
were to explore the potential usefulness of
MCMV infection as a means of detecting deficits
in the immune response and to use immunosup-
pressive treatment to identify host defense
mechanisms which are active in protecting
against MCMV-induced disease.
A variety of tests are available to assess the
functional integrity of various segments of the
immune system. Such tests are commonly ap-
plied whenever it is suspected that host defense
mechanisms are compromised by disease, expo-
sure to drugs or other toxic chemicals, genetic
defects, or other circumstances (2, 12, 22, 36).
Due to the complexity of the immune response,
no single assay is available to test the compe-
tence of the entire system, and it has been
suggested that a tier of tests be developed,
particularly when chemicals are to be screened
for immunotoxicity (4, 36). Two of the most
commonly used tests for immunocompetence
are lymphocyte transformation by polyclonal
mitogens and antibody responses to sheep eryth-
rocytes. It is somewhat difficult to predict what
the results of these tests mean in terms of
enhanced risk of acquiring infectious, neoplas-
tic, or autoimmune diseases. Susceptibility to
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MCMV might provide a useful test which would
directly measure enhanced susceptibility to an
infectious agent and therefore be of value in a
series of tests designed to measure immunotoxi-
city. To explore this possibility, we studied the
effects of cyclophosphamide (CY), a known
immunosuppressant, on mortality and pathogen-
esis during acute MCMV infection.
In addition, we studied the effects of CY on
parameters used to assess the activity of certain
segments of the immune defense system. We
correlated the effects of CY on particular im-
mune functions with effects on MCMV disease
in an effort to elucidate the mechanisms which
control acute MCMV and to determine what
immunological functions must be depressed to
enhance MCMV infection. Attention was fo-
cused on the functional integrity of lymphocytes
with respect to blastogenic response and natural
killer (NK) cell activity, since these are thought
to be important in host defenses against cyto-
megaloviruses (3, 8, 15, 26, 27).
Although human cytomegalovirus infections
after immunosuppression are largely attributable
to reactivation of latent viruses, most studies
indicate that infections also occur in previously
seronegative individuals, who presumably expe-
rienced a primary infection while receiving im-
munosuppressive treatment (5, 6, 20, 21, 25).
The present work with acute MCMV may pro-
vide insights into that particular clinical situation
and into the host defense mechanisms which
protect ordinary individuals from symptomatic
human cytomegalovirus infections.
MATERIALS AND METHODS
Virus. The Smith strain of MCMV was obtained
from the American Type Culture Collection (Rock-
ville, Md.) and was passaged through mouse salivary
glands. Virulent virus pools, which were used through-
out this study, were obtained by making a 10% (wt/vol)
extract of salivary glands 2 to 3 weeks postinfection.
Detailed procedures for producing virus pools have
been described previously (33). To determine infectiv-
ity titers of virus pools, plaque assays were carried out
as follows. Confluent monolayers of secondary mouse
embryo fibroblasts were produced in 25-cm2 tissue
culture flasks by previously described methods (34).
Serial dilutions of fluids containing MCMV were made
in maintenance medium containing medium 199
(GIBCO Laboratories, Grand Island, N.Y.), 3% fetal
calf serum, 200 U of penicillin per ml, 200 jLg of
streptomycin per ml, and 0.525% sodium bicarbonate.
Appropriate dilutions were added in 0.5-ml volumes to
each of two cell monolayers, and virus was allowed to
adsorb for 2 h at 37°C. The inoculum was removed,
and monolayers were overlayed with 0.8% gum trag-
acanth (Sigma Chemical Co., St. Louis, Mo.) in main-
tenance medium, incubated for 5 days at 37°C, washed
successively with 0.85% saline, fixative containing
ethanol, acetic acid, and 10o formalin (6:2:1), and 1%
crystal violet in water. Plaques were counted with the
aid of a dissecting microscope.
Mice. Outbred CD-1 mice (Charles River Breeding
Laboratories, Inc., Wilmington, Mass.) were 5 to 8
weeks old at the time of use. Inbred C3H/HeJ mice
were obtained from Jackson Laboratories, Bar Har-
bor, Me., and were used when they were 6 to 10 weeks
old. Mice were given various regimens of virus or CY
(Cytoxan; Mead Johnson & Co., Evansville, Ind.) or
both intraperitoneally, and mortalities were recorded
daily for 20 days after infection.
Detection of virus in target organs. In some cases,
lung, liver, and spleen were removed from infected
mice, and 10%o (wt/vol) homogenates were made with
sterile sand, mortar, pestle, and maintenance medium.
Extracts were clarified by low-speed centrifugation,
10o dimethyl sulfoxide was added, and small portions
were stored at -70°C. Organ extracts were assayed for
virus in the same manner described for virus pools.
Histological preparations. Lungs were fixed in situ,
as previously described (32). Spleen, liver, and thymus
were removed from the animal, cut in small pieces,
and placed in fixing solution (0.103 M glutaraldehyde,
0.1125 M sodium cacodylate). The solution was
changed once, and tissues were stored in the same
fixative. Tissues were processed by the standard par-
affin technique for histopathological evaluation.
Lymphocyte response to mitogens. Spleen cells from
uninfected mice treated with 150 mg of CY per kg of
body weight and untreated mice were removed, and
responsiveness to phytohemagglutinin (PHA) (Well-
come Research Laboratories, Beckenham, England)
and bacterial lipopolysaccharide (LPS) (Escherichia
coli 0128:B12; Difco Laboratories, Detroit, Mich.)
was assessed in vitro by uptake of [3H]thymidine. This
assay was performed as previously described (31)
except that erythrocytes were removed from spleen
cell suspensions by using lysing buffer (0.15 M NH4Cl,
0.1 M KHCO3). For a given spleen, the mean of counts
from triplicate microtiter wells containing medium and
cells was subtracted from the mean of counts from
triplicate wells containing mitogen and cells to obtain
counts due to mitogen stimulation.
Assay for NK cell activity. YAC-1 cells were labeled
by suspending 5 x 106 cells in 0.1 ml of RPMI 1640
supplemented with 10o fetal calf serum and adding 2
mCi of 5"Cr as sodium chromate in 0.1 ml of saline
(New England Nuclear Corp., Boston, Mass.). The
suspension was incubated for 1 h at 37°C in 5% CO2
with gentle agitation at 10-min intervals. Cells were
then pelleted by low-speed centrifugation, washed
three times with RPMI 1640, and resuspended in
RPMI 1640 plus 10% fetal calf serum (10' cells per ml).
Spleen cells were prepared by the same methods used
for the mitogen assay, suspended in RPMI 1640 (5 x
106 cells per ml), and dispensed in triplicate V-bottom
microtiter wells (0.1 ml/well). To measure spontane-
ous release, 5 x 10W unlabeled YAC-1 cells in 0.1 ml
were substituted for spleen cells; to measure total
release, 0.1 ml of 0.5% Triton X-100 (Sigma) in dis-
tilled water was substituted for the spleen cell suspen-
sion. The microtiter plate was centrifuged at 300 x g
for 5 min, incubated for 4 h at 37°C in 5% CO2, and
centrifuged again. The amount of 5'Cr in 0.1-ml sam-
ples of supernatant from each well was determined
with a Beckman Gamma 4000 counting system. The
specific cytolysis was calculated by averaging the
counts for triplicate wells and applying the following
formula:
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% t = mean counts with spleen cells - mean spontaneous release x 100
mean total release - mean spontaneous release
RESULTS
Effect of CY on MCMV-induced mortality. To
determine when infected mice would be most
vulnerable to immunosuppression, groups of 14
to 16 CD-1 mice were treated with a single
intraperitoneal injection of either 150 or 100 mg
of CY per kg, given on various days before or
after infection with 105 PFU ofMCMV. Figure 1
shows that little or no mortality was observed in
animals treated with CY 1 or 2 days before
infection or 6 to 9 days after infection. Maximum
mortality (80 to 90%) was observed when CY
was given 2 to 4 days after infection. Most
animals died 8 to 14 days after infection; those
which received CY 4 days after MCMV tended
to die later than those which received CY 2 days
after MCMV. No deaths occurred among mice
which were infected with 105 PFU of MCMV
alone or among uninfected mice treated with 150
mg of CY per kg.
Figure 2 shows the effect of various doses of
CY given 3 days after MCMV infection. Maxi-
mum mortality was observed when CD-1 mice
were given 100 or 150 mg of CY per kg. There
was no difference in the percent mortality seen
in these two groups. The lowest effective con-
centration tested was 80 mg of CY per kg.
Figure 3 shows the effect of varying the virus
dose on mortality observed in groups of mice
given 150 mg of CY per kg 1 or 2 days before
infection or 3 days after infection. As previously
indicated, mortality was enhanced when CY was
given 3 days after infection of CD-1 mice with
105 PFU but not when it was given 1 day before
infection. Mortality was also enhanced when CY
was given 3 days after infection with 4 x 104
PFU but not when lower doses of virus were
given. The effect of giving CY before infection
with these lower doses was not tested, since no
effect was seen when CY was given before
infection with 10 PFU. By raising the virus dose
to 2 x 105 PFU, enhanced mortality could be
seen in mice given CY 1 day before infection as
well as in those given CY 3 days after infection.
The latter group showed the greatest enhance-
ment (100% mortality) over non-CY-treated con-
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DAY OF CYCLOPHOSPHAMIDE TREATMENT RELATIVE TO DAY OF INFECTION
FIG. 1. Mortality in mice given a single dose of either 150 (0) or 100 (A) mg of CY per kg of body weight on
various days relative to the day of infection with 10' PFU of MCMV. Each data point represents the percent
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FIG. 2. Effects ofdose ofCY on enhancement of MCMV-induced mortalities. Groups of 15 mice were treated
with doses ranging from 20 to 150 mg/kg 3 days after infection with 10' PFU of MCMV. a, P < 0.01 with a
nonparametric Williams test. Numbers over bars represent number of mice dead out of number treated.
still further to 106 PFU increased the mortality
seen in animals treated with CY 1 day before
infection. However, because the number of
deaths in untreated animals also increased, the
difference in mortality between groups treated
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FIG. 3. Effect of virus dose on CY enhancement of mortality. CD-1 or C3H mice were given 150 mg ofCY per
kg at various times relative to infection with various doses of virus. a, P = 0.003; b, P = 0.0001 when compared
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FIG. 4. Virus titers in target organs of mice infect-
ed with 2 x 105 PFU and given 150 mg of CY per kg 2
days after infection or left untreated. Each data point
represents the mean and standard error of the log of
PFU per gram tissue for three to six mice.
groups was not statistically different when the
virus dose was 106 PFU as compared with 2 x
105 PFU.
Similar results were seen when C3H mice
were infected with 5 x 105 or 105 PFU and
treated with 150 mg of CY per kg either 2 days
before or 3 days after infection (Fig. 3). Com-
pared with untreated controls, animals given the
lower dose of virus showed enhanced mortality
only when CY was given after infection. At the
higher dose, both treatment regimens resulted in
greatly enhanced mortality compared with un-
treated controls.
Effects of CY and MCMV infection on target
organs. The effect of CY on production of virus
in various target organs was determined by
treating CD-1 mice with 150 mg of CY per kg 2
days after infection. Infected mice treated with
CY or untreated were sacrificed, lungs, livers,
and spleens were removed, and virus titers were
determined for individual organs. The effects of
CY treatment on virus titers in organs removed
5, 6, and 7 days after infection were analyzed by
using analysis of variance (Fig. 4). In all organs,
CY treatment caused an increase (P < 0.0005) in
virus titers. This effect was most dramatic in the
liver and spleen, in which for all days tested
there was a 100- to 1,000-fold increase in the
mean PFU per gram of tissue in CY-treated
animals compared with untreated animals. This
magnitude of increase was also seen in lungs
taken 5 days after infection, but differences in
lungs diminished to 5 to 50-fold on subsequent
days. A significant interaction between CY
treatment and day of titration postinfection was
not seen, with the possible exception of the lung
in which this interaction was marginally signifi-
cant (P = 0.09) due to the lack of an effect ofCY
7 days postinfection.
To determine whether the enhanced mortality
seen in infected animals treated with CY was
reflected in organ weights and histopathology,
CD-1 mice infected with 105 PFU and treated
with 150 mg of CY per kg 3 days after infection
were sacrificed 5, 7, and 10 days after infection
along with mice which received virus only, mice
which received CY only, and untreated controls.
Lung, liver, spleen, and thymus were removed
from all animals, the latter three organs were
weighed, and samples of organs removed on
days 5 and 7 after infection were prepared for
histopathological study.
After MCMV infection, spleen and liver
weights were slightly higher than those of unin-
fected normal animals (Fig. 5), but differences
between these two groups were never statistical-
ly significant. At all time points, whole body
weights, as well as the weights of spleen and
thymus, were significantly depressed in animals
treated with MCMV plus CY compared with
both untreated infected and normal uninfected
mice. Liver weights in mice treated with MCMV
plus CY were significantly depressed on days 7
and 10 postinfection. Some of this difference
could be attributed to CY treatment alone, since
body and organ weights were significantly de-
pressed in this group 5 days after infection, but
body, liver, and thymus weights in animals
treated only with CY were not significantly
different from controls on days 7 and 10 after
infection, and spleen weight was not significant-
ly different on day 10.
There were no notable microscopic lesions in
any of the lung sections from any of the treat-
ment groups. No significant lesions were noted
in the livers of untreated mice or mice given CY
only. Scattered pyknotic, degenerate hepato-
cytes (some of which contained intranuclear
inclusions), focal collections of mononuclear
cells, and Kupffer cell hyperplasia were ob-
served in mice given MCMV or MCMV plus
CY. Differences between these two groups were
not striking despite the difference noted in liver
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FIG. 5. Effects ofCY treatment and MCMV infection on wet weight of organs. Each data point represents the
mean and standard error of organ or body weights from seven mice. Symbols: A, 10, PFU of MCMV; 0, 105
PFU ofMCMV plus 150 mg ofCY per kg 3 days after infection; K, 150 mg of CY per kg; 0, no treatment. a, Sig-
nificantly different from control (P < 0.05 with Dunnett's test) by using the error estimate from a two-way
analysis of variance in randomized blocks.
weights. In the spleen, CY or MCMV produced
a minimal to moderate lymphocyte depletion.
Lesions caused by MCMV were slightly more
severe and included a reticular-like cell hyper-
plasia and scattered necrotic cells throughout
the parenchyma. When MCMV and CY were
given to the same mouse, lymphocyte depletion
was more severe, and red pulp necrosis, lym-
phocyte necrosis, and intranuclear inclusions in
reticular cells were also observed. This picture
is consistent with the observed drop in spleen
weights in this group. Because of its central role
in the immune response, the thymus was exam-
ined in these studies, even though it is not
notable as a target organ in the sense of MCMV
production (M. Selgrade, Ph.D. thesis, Univer-
sity of Wisconsin, Madison, 1973). MCMV
caused minimal lymphocytic depletion, whereas
CY and CY plus MCMV caused moderate to
severe lymphocytic depletion. This is also con-
sistent with the differences observed in thymus
weight.
Effects of CY on immune responses. Uninfect-
ed mice were treated with 150 mg of CY per kg,
spleens were removed on various days after
infection from CY-treated and control mice, and
the responses of lymphocytes from these two
groups to PHA and LPS were determined and
compared (Table 1). The effect of CY on re-
sponses to both mitogens appeared to be bipha-
sic. One day after CY treatment, responses were
depressed. With each successive day up to 4
days, the degree of depression diminished such
that there was no difference between treated and
untreated mice on day 4. However, 9 days after
treatment, significant depression in both mito-
gen responses was again observed. Again, the
degree of depression diminished on successive
days; recovery from this second phase of de-
pression was more rapid for LPS than for PHA.
The effects of CY treatment on MCMV-in-
duced nonspecific cytotoxic activity of spleen
cells were also assessed by using the 51Cr re-
lease assay typically employed to detect NK cell
activity. C3H mice were treated with 150 mg of
CY per kg 2 days before or 1 or 3 days after
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TABLE 1. Effects of CY on mitogen response of spleen cells from uninfected mice
Days after PHA LPS
CY Control CY-treated % Depression Control CY-treated % Depression
treatment (cpm x 104)a (cpm x 104)a due to CY (cpm x 104)a (cpm x 104)O due to CY
1 5.50 ± 0.74 (6) 1.36 ± 0.40 (9)b 75 7.22 ± 1.17 (6) 0.57 ± 0.23 (9)b 92
2 7.74 ± 1.22 (4) 3.88 ± 0.71 (7)' 50 7.92 ± 0.91 (12) 3.53 ± 0.56 (12)b 55
3 8.08 ± 1.56 (7) 4.77 ± 1.29 (7)' 41 8.13 ± 1.23 (7) 5.01 ± 1.37 (7)b 38
4 7.98 ± 2.05 (5) 6.68 ± 0.65 (6) 16 9.28 + 0.98 (6) 7.41 ± 0.81 (6) 20
9 11.57 ± 1.08 (7) 1.20 ± 0.31 (8)b 90 10.50 ± 1.22 (7) 5.09 ± 1.14 (8)b 52
12 4.72 ± 0.98 (6) 1.08 ± 0.41 (7)b 77 4.20 ± 0.31 (11) 3.46 ± 0.51 (12) 18
15 8.18 ± 1.20 (10) 6.48 ± 0.95 (12) 21 8.63 ± 0.60 (11) 6.59 ± 0.83 (12) 24
19 8.47 ± 1.09 (11) 7.02 ± 1.34 (11) 17 7.38 ± 1.63 (11) 6.99 ± 1.72 (11) 5
23 14.03 ± 1.39 (9) 10.69 ± 1.40 (9)' 24 11.31 ± 0.87 (9) 11.92 ± 1.08 (9) 0
a Mean ± standard error of net cpm (cpm for mitogen stimulated cells - cpm for unstimulated cells) for
number of animals indicated in parentheses.
b Depressed when compared with control (P < 0.05).
c Depressed when compared with control (P < 0.10). Statistical methods were the same as those used for Fig.
5.
infection with 104 PFU of MCMV. Figure 6
compares the cytolytic activity in spleen cells
from untreated mice and CY-treated mice on
various days after infection. This activity in
animals treated with CY 2 days before infection
was significantly depressed on days 1 and 3 after
infection but had recovered and reached peak
activity at the same time untreated mice reached
peak activity 5 days after infection. In contrast,
NK activity in animals treated with CY 1 and 3
days after infection never reached the peak seen
on day 5 in untreated animals. Activity in these
animals was profoundly depressed on day 5 and
remained depressed on day 8, although the dif-
ference between untreated and treated was not
as great due to the normal waning ofNK activity
at this time. Similar trends were observed when
animals received 105 PFU of MCMV, which
caused a higher level of NK cell activity in
untreated animals than was observed after infec-
tion with 104 PFU.
DISCUSSION
The data presented here show the effects of
several different regimens of CY treatment on
MCMV infection and MCMV-related parame-
ters. Enhanced mortality was demonstrated in
animals given single doses of CY ranging from
80 to 150 mg per kg. Such enhancement was
more efficiently achieved when animals received
CY after virus challenge. Our data on mortality
are similar to those of Peller and Goetz (24), who
demonstrated enhanced mortality and increased
virus titers in the liver in MCMV-infected mice
given a single dose of 80 mg ofCY per kg on the
day of infection or three doses given on days -2,
-1, and 0 relative to infection. Agatsuma (1)
also demonstrated enhanced mortality in
MCMV-infected mice when three doses of 200
mg of CY per kg were given on days 7, 11, and
15 after infection.
In addition to enhanced mortality, virus titers
in lung, liver, and spleen were elevated by CY
treatment, supporting the thesis that deaths oc-
cur as a result of CY enhancement of MCMV
infection in these vital organs rather than
MCMV enhancement of CY toxicity. Also, the
wet weights of liver, spleen, and thymus in
infected mice treated with CY were depressed
compared with untreated infected mice and, at
some time points, with uninfected CY-treated
mice. Although gross differences in histopathol-
ogy were minimal, decreased liver and spleen
weights in CY-treated, infected animals were
probably due to more extensive virus-induced
necrosis and a depressed inflammatory re-
sponse. The depression of spleen and thymus
weight in CY-treated animals with and without
virus probably also reflects loss of leukocytes
due to CY depression of bone marrow function.
The fact that spleen and thymus weight in ani-
mals given MCMV plus CY remained depressed
longer than in animals given CY alone suggests
that MCMV somehow prolongs recovery of
these organs to normal weight after CY treat-
ment and therefore may act synergistically with
CY in depressing thymic and splenic functions.
Decreased body weight in these animals proba-
bly reflects a general cachexia due to the sever-
ity of the infection.
The effects of CY on production of MCMV-
neutralizing antibody were not examined, since
such antibody is normally not detected until 14
to 33 days after infection (23) and therefore
could not have affected the outcome in this
study, in which mice died 10 to 14 days after
infection. Because mitogen-induced lymphocyte
proliferation is often used to test compounds for
immunotoxicity, the effects of CY on the re-
sponse of lymphocytes to T (PHA) and B (LPS)
cell mitogens were included in this study to
determine whether such tests are predictive of
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FIG. 6. Effect of 150 mg of CY per kg given on
various days relative to infection on MCMV-induced
NK cell activity. Symbols: A, virus only; 0, CY given
2 days before infection; CY given 1 day after
infection; O, CY given 3 days after infection. Data
points represent the mean standard error for three to
six mice. a, Significantly different from virus-only
group (P < 0.05). On day 8, the activity in the group
treated with CY on day 3 was significantly lower than
that of mice treated with CY on day 1. Statistical
analysis was performed by using a one-way analysis of
variance for each day tested. For days 3, 5, and 8,
treatment effects were subtested with Duncan's multi-
ple range test.
enhanced susceptibility to MCMV. Uninfected
mice were used because MCMV itself greatly
depresses responses to PHA and LPS for 2 to 3
weeks after infection (31). Both mitogen re-
sponses were initially depressed by CY treat-
ment, recovered with time after treatment, and
then showed a second phase of depression and
recovery. This biphasic response to CY may
reflect the fact that more than one cell type is
involved in the mitogen response. These may
turn over at different rates and thus be affected
at different times after CY treatment.
Figure 1 predicts that CY depression of the
immune responses relevant to MCMV suscepti-
bility must be fairly short-lived, since mice given
CY 1 day before infection were unaffected. If the
depression of mitogen responses on various
days after CY treatment had not been biphasic
(Table 1), a good correlation between depressed
mitogen responses and enhanced susceptibility
would have been obtained. However, the sec-
ond phase of depressed mitogen responses,
which began around day 9, mars this correlation.
Depressed mitogen responses were observed at
many of the time points up to 9 to 12 days after
CY treatment, a period of time adequate to
cover the entire acute stage of MCMV infection,
even in animals given CY 1 day before infection.
The importance of the time of administration of
CY relative to infection as it affects the outcome
of the disease (Fig. 1) could be more easily
explained by the effect of the time of CY admin-
istration on MCMV-augmented nonspecific cy-
tolytic activity (Fig. 6). Animals treated with CY
2 days before infection recovered this activity
apparently in time to recover from the disease,
whereas those treated with CY 1 and 3 days after
infection did not recover this cytolytic activity
and experienced a more severe disease.
Without further attempts to characterize the
cell type responsible for target cell lysis, we
assume that the activity we observed was due to
NK cells for several reasons. The cytotoxicity
was directed against non-H-2-related cells in the
absence of viral antigen, eliminating cytotoxic T
cells as a possible effector. Also, the curve
obtained for untreated mice in Fig. 6 corre-
sponds very well to that obtained for NK cell
activity by Quinnan and Manischewitz (26). In
contrast, it does not correspond to a curve
obtained by Schleupner et al. (30), in which
enhanced macrophage cytotoxicity for tumor
cells after MCMV infection reached a peak 3
days postinfection and remained at this level
until approximately 21 days postinfection.
Quinnan and Manischewitz (26, 28) were the
first investigators to suggest an important role
for NK cells in host defenses during the acute
stage of MCMV infection. Bancroft et al. (3)
provided more evidence in support of this thesis
by demonstrating a significant correlation be-
tween resistance to MCMV and the degree of
NK cell augmentation by the virus in 10 strains
of susceptible and resistant mice. The temporal
relationship demonstrated in the present study
between time of CY administration, enhanced
mortality, and decreased NK cell activity pro-
vides more evidence that NK cells have an
important influence on the outcome of acute
MCMV infection. The relationship observed
here between time of CY administration and
depression of NK cell activity correlates well
with data presented by Riccardi et al. (29) which
showed maximum depression of spontaneous
NK cell activity 4 days after treatment with 240
mg of CY per kg.
It has been demonstrated that immunosup-
pressive treatment with radioactive strontium
enhances MCMV infection without depressing
NK cell activity (17). In addition to NK cell
activity, several other immune defense mecha-
nisms are thought to influence the outcome of
MCMV infections. These include macrophage
activity (35), cytotoxic T cell activity (27), and
interferon production (16). Any treatment which
reduced these responses might also enhance
mortalities and virus target organ titers due to
MCMV. This illustrates the need to include tests
for immunological function along with disease
susceptibility tests in any tier of tests designed
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to assess immunotoxicity. These are needed to
determine what aspects of the immune response
are affected by a particular treatment and to
verify that enhanced mortality is a result of
immunosuppression. It also suggests that al-
though NK cell activity may play an important
role in the host defense against MCMV, there
are other immune responses which also contrib-
ute to host protection.
From our data, we conclude that the effects of
CY on MCMV susceptibility corresponded well
with effects on thymus, spleen, and liver wet
weight and virus titers in lung, spleen, and liver
and with CY effects on virus-induced NK cell
activity. Good correlation was not obtained be-
tween effects of CY on MCMV susceptibility
and CY effects on responses of lymphocytes to-
B and T cell mitogens, nor were differences in
pathology particularly striking. NK cells are
thought to play an important role in host de-
fenses against tumor cells as well as other virus-
es. In addition, other immune responses thought
to be important host defenses against MCMV,
such as macrophage activity, cytotoxic T cell
activity, and interferon production (16, 27, 35),
are also thought to have a role as antitumor
defense mechanisms (11). Susceptibility to
MCMV, coupled with an assay for NK cell
activity, as well as some of the above-mentioned
immune responses, might therefore be very use-
ful parameters to include in a series of tests
designed to screen chemicals for immunotoxici-
ty. MCMV would provide a disease susceptibil-
ity test which could be assessed much more
rapidly than increased tumor susceptibility and
could perhaps provide similar answers.
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